FDA: Samsca may cause irreversible liver damage

FDA: samsca may cause irreversible liver damage
Patients who take Samsca (tolvaptan) may be at elevated risk for significant liver injury, according to a Jan. 25 safety alert issued by the U.S. Food and Drug Administration.

(HealthDay)—Patients who take Samsca (tolvaptan) may be at elevated risk for significant liver injury, according to a Jan. 25 safety alert issued by the U.S. Food and Drug Administration.

The FDA and Otsuka notified health care providers of this potential risk after three patients with Autosomal Dominant (ADPKD) participating in a drug trial developed significant increases in serum alanine aminotransferase, along with significant increases in serum total bilirubin. The patients were taking a higher dose (90 mg in the morning and 30 mg in the afternoon) than the 60-mg dose approved for hyponatremia. Samsca is not approved for treating of ADPKD.

An external panel of liver experts determined that tolvaptan was most likely the culprit in these three cases; all of the patients improved once they stopped taking the drug.

" should perform liver tests promptly in patients who report symptoms that may indicate liver injury," the authors write. "If hepatic injury is suspected, Samsca should be promptly discontinued, appropriate treatment should be instituted, and investigations should be performed to determine probable cause. Samsca should not be re-initiated in patients unless the cause for the observed is definitively established to be unrelated to treatment with Samsca."

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Added benefit of vedolizumab is not proven

4 hours ago

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments